The Impact of Physical (In)Activity on Sleep Quality
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- Change in sleep quality (phase 1)
研究概览
简要总结
The proposed research will examine the role of physical activity (PA) on altering sleep quality (SQ) while systematically examining novel mechanisms that may drive changes in SQ. Specifically, the study will examine how a 2 week reduction in PA alters sleep quality in young, healthy individuals. Additionally, during this reduction in PA, the study will examine changes in inflammation, oxidative stress, and sympathetic activity to identify potential mechanisms for alterations in sleep quality.
详细描述
Sleep, which makes up approximately one third of an individual's life, plays a vital role in normal bodily functioning by regulating metabolic and endocrine function. Disturbed sleep, defined as any alteration to normal sleep patterns, is highly prevalent, affecting 35% and 41% of the general population in the United States and has been linked to poor cardiovascular health, diabetes, obesity, dyslipidemia, and hypertension. Young adults are a population at high risk for disturbed sleep-related health outcomes due to negative lifestyle behaviors such as alcohol consumption, drug use, study patterns, and excessive screen time that remain with advancing age. Due to the importance of improving or maintaining health outcomes through adequate sleep quality (SQ), the proposed research will examine the role of physical activity (PA) on altering SQ while systematically examining novel mechanisms that may drive changes in SQ. Specifically, this study will examine how alterations (increases and decreases) in PA impact SQ and how these alterations modify inflammation, oxidative stress, and sympathetic stimulation in young adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy individuals with average weekly step count greater than 7500
- •Low risk of cardiovascular, pulmonary, and metabolic disease
排除标准
- •Individuals with cardiovascular, pulmonary, and metabolic disease
- •Individuals taking medications that may affect cardiovascular, pulmonary, and metabolic function
- •Diet differs substantially from typical diet, significant calorie restriction, or vitamin/mineral deficiencies
- •Pregnant women
- •Prisoners
结局指标
主要结局
Change in sleep quality (phase 1)
时间窗: Day 7 to Day 21
Evaluation of sleep efficiency (the ratio of total sleep time to the total time recorded in which the subject was not asleep (i.e. brief awakenings))
Change in sleep quality (phase 2)
时间窗: Day 21 to Day 28
Evaluation of sleep efficiency (the ratio of total sleep time to the total time recorded in which the subject was not asleep (i.e. brief awakenings))
次要结局
- Level of Tumor Necrosis Factor Alpha in blood(Measured on Day 7, Day 14, Day 21, Day 28)
- Level of Interleukin-6 in blood(Measured on Day 7, Day 14, Day 21, Day 28)
- Level of Interleukin-1 in blood(Measured on Day 7, Day 14, Day 21, Day 28)
- Level of Norepinephrine in blood(Measured on Day 7, Day 14, Day 21, Day 28)
- Level of Epinephrine in blood(Measured on Day 7, Day 14, Day 21, Day 28)
- Level of Lipid peroxidation in blood(Measured on Day 7, Day 14, Day 21, Day 28)
- Protein oxidation in blood(Measured on Day 7, Day 14, Day 21, Day 28)
- Change in Lower Limb Vascular Function(Measured on Day 7, Day 14, Day 21, Day 28)
- Change in Upper Limb Vascular Function(Measured on Day 7, Day 14, Day 21, Day 28)
- Change in Leg Vascular Function(Measured on Day 7, Day 14, Day 21, Day 28)